Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma

Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma

# Background Further research is needed to determine real-world costs of first-line (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), modified FFX (mFFX), and gemcitabine with nab-paclitaxel (GnP). # Objectives To describe healthcare costs by treatment reg...

Full description

Saved in:
Bibliographic Details
Main Authors: Syvart Dennen, Marty Masek, Paul Cockrum, Elizabeth Nagelhout, Ravi Paluri
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2025-08-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://doi.org/10.36469/001c.142403
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items